News und Analysen
DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter
DGAP-News: Gerresheimer AG: Gerresheimer hebt nach starkem 1. Quartal Umsatzprognose für 2022 auf zweistelliges Wachstum an
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t been
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t been
DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Premier, Inc. to Report Fiscal 2022 Third-Quarter Results and Host Conference Call on May 3, 2022
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 third quarter on Tuesday, May 3, 2022, at approximately 6:30 a.m. ET. The company will also
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)
Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the use of the test to patients diagnosed
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma
Agilent Technologies Inc. (NYSE: A) today announced it has expanded CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma
DGAP-News: Evotec SE to announce results for fiscal year 2021 on 12 April 2022
DGAP-News: Evotec SE: Bekanntgabe der Ergebnisse für das Geschäftsjahr 2021 am 12. April 2022
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
Agilent Joins AMBIC to Advance Biomanufacturing
Agilent Technologies Inc. (NYSE: A) announced today that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC). Joining AMBIC demonstrates the company’s
Acadia Healthcare Announces Christopher Hunter as New Chief Executive Officer
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that its Board of Directors has named Christopher Hunter as the Company’s new Chief Executive Officer. He will join Acadia on April
Novocure to Report First Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
Regulatory News:
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022. Management will hold a conference call
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022. Management will hold a conference call
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the monotherapy arm of the ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrating that Rubraca as
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
Regulatory News:
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a business update.
“The company